Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1

Conditions

Lung Neoplasms 3Urinary Bladder Neoplasms 2Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Sarcoma 1Neoplasms, Germ Cell and Embryonal 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Melanoma 1Esophageal Neoplasms 1

Interventions

Specimen Handling 40Biopsy 39Magnetic Resonance Spectroscopy 31Cyclophosphamide 21aldesleukin 20fludarabine 16fludarabine phosphate 13Leucovorin 12Fluorouracil 12Interleukin-2 11Paclitaxel 9Melphalan 9Oxaliplatin 8trastuzumab deruxtecan 7Irinotecan 7X-Rays 6Taxes 6Nivolumab 6olaparib 5Ipilimumab 5CTLA-4 Antigen 5trametinib 4Neoadjuvant Therapy 4Floxuridine 4Doxorubicin 4Chemotherapy, Adjuvant 4Carboplatin 4veliparib 3talazoparib 3pembrolizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Neoplasm Metastasis × Tetrahydrouridine × Clear all
NCT02839694 2018-07-05

Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
DermatologicSarcoma

Melanoma, Neoplasm Metastasis, Neoplasms, Germ Cell and Embryonal, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡